Damien, Charlotte
Leitinger, Markus
Kellinghaus, Christoph
Strzelczyk, Adam
De Stefano, Pia
Beier, Christoph P.
Sutter, Raoul
Kämppi, Leena
Strbian, Daniel
Taubøll, Erik
Rosenow, Felix
Helbok, Raimund
Rüegg, Stephan
Damian, Maxwell
Trinka, Eugen
Gaspard, Nicolas
Funding for this research was provided by:
Fonds Erasme
Innoviris
Swiss National Foundation (320030_169379)
Research Fund of the University Basel
The Scientific Society Basel
The Gottfried Julia Bangerter-Rhyner Foundation
Michael Foundation
Finnish Neurological Society
Finnish Cultural Foundation
HUS Neurocenter
Boehringer Ingelheim
GSK
Biogen
Eisai
Novartis
Red Bull
Bayer
UCB
Austrian Science Fund
Österreichische Nationalbank
Belgian National Research Fund
Angelini
Article History
Received: 14 July 2023
Accepted: 11 December 2023
First Online: 4 January 2024
Declarations
:
: The study was registered at the Ethics Committee of Erasme Hospital (Committee Reference Number: 406; Protocol Number: CCB: B4062020000170; P2020/483).The study was also registered in PRS with number NCT05839418.In some countries, informed consent was waived due to the non-interventional character of this study. In some countries, informed consent is necessary purely due to the prospective nature of this study and due to data sharing regulations.This study will be performed in line with the principles of the Declaration of Helsinki.
: Not applicable.
: Christoph Kellinghaus has received speaker’s honoraria from Angelini Pharma, Eisai, Jazz Pharmaceuticals, UCB, LivaNova. He has served on advisory boards for Angelini Pharma, Eisai and Marinus Pharma.Adam Strzelczyk received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz (GW) Pharmaceuticals, Marinus Pharma, Precisis, Takeda, UCB (Zogenix) Pharma, and UNEEG medical. AS is editor-in-chied of Clinical Epileptology and editorial board member of Neurological Research and Practice.Raoul Sutter received research grants from the Swiss National Foundation (No 320030_169379), the Research Fund of the University Basel, the Scientific Society Basel, and the Gottfried Julia Bangerter-Rhyner Foundation. He received personal grants from UCB-pharma and holds stocks from Novartis, Roche, Alcon, and Johnson & Johnson.Leena Kämppi reports speaker’s honoraria from UCB, Merck and Eisai and personal grants from Michael Foundation, Finnish Neurological Society, Finnish Cultural Foundation and HUS Neurocenter.Daniel Strbian serves in the advisory board for AstraZeneca, Alexion, Janssen, BMS, Orion, CLS Behring, Herantis Pharma and received unrestricted education grant from Boehringer Ingelheim.Stephan Rüegg has received honoraria from serving on the scientific advisory boards of Arvelle/Angelini, Bial, Eisai, GW, and UCB-pharma, and from serving as a consultant for Arvelle/Angelini, Eisai, Pfizer, Novartis, Sandoz, and UCB-pharma. He has received speaker’s honoraria from Eisai and Novartis. He does not hold any stocks of any pharmaceutical industries or manufacturers of medical devices. He disclosed that he is co-editor-in-chief of Clinical Epileptology (01/01/2022; no payments).Eugen Trinka reports paid consultancy from Arvelle, Argenx, Angelini, Clexio, UCB, Eisai, Epilog, Bial, Medtronic, Everpharma, Biogen, Takeda, Jazz, Liva-Nova, Newbridge, Sunovion, GW Pharmaceuticals/Jazz, Marinus; Research funding (directly, or to institution) from GSK, Biogen, Eisai, Novartis, Red Bull, Bayer, and UCB; Speaker’s honoraria from Arvelle, Angelini, GSK, GW Pharmaceuticals, Böhringer Ingelheim, Eisai, Epilog, Bial, Everpharma, UCB, Liva-Nova, Newbridge, Hikma, Novartis, and Sanofi. He is CEO of Neuroconsult Ges.m.b.H. Grants from Austrian Science Fund (FWF), Österreichische Nationalbank, and the European Union.Nicolas Gaspard reports speaker’s honoraria from UCB Pharma and Angelini Pharma; paid consultancy from UCB Pharma and Marinus and research funding (directly, or to institution) from UCB and Angelini; grants from Belgian National Research Fund; Fonds Erasme pour la Recherche Médicale and INNOVIRIS; honoraria from MedLink Neurology.Other authors declare that they have no competing interest.